Embecta Corp. (EMBC) stock
EMBCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 15/3080% below fair value
$6.15−0.10 (-1.60%)
Close on Nov 17, 2026Market cap $348.46MP/E 4.2Yield 9.76%
Embecta revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Embecta's revenue for the twelve months ending Jun 30, 2026 was $1.02B, down 7.6% year over year. For fiscal 2025 it was $1.08B, down 3.8% from the year before. The highest annual figure on record is $1.17B in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.08B | -3.8% |
| FY2024 | Sep 30, 2024 | $1.12B | +0.2% |
| FY2023 | Sep 30, 2023 | $1.12B | -0.8% |
| FY2022 | Sep 30, 2022 | $1.13B | -3.1% |
| FY2021 | Sep 30, 2021 | $1.17B | +7.4% |
| FY2020 | Sep 30, 2020 | $1.09B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $271.70M | -8.1% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $221.80M | -14.4% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $261.20M | -0.3% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $264.00M | -7.7% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $295.50M | +8.4% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $259.00M | -9.8% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $261.90M | -5.6% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $286.10M | +1.5% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $272.50M | -4.8% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $287.20M | +3.6% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $277.30M | +0.6% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $281.90M | +2.7% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $286.10M | -1.7% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $277.10M | +0.9% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $275.70M | -4.7% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $274.60M | -8.7% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $291.10M | -1.3% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $274.50M | -3.4% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $289.30M | +1.4% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $300.80M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $295.00M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $284.20M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $285.30M | – |
See a number that looks wrong?